.jpg?itok=W6nsHDXV)
Company search
Overview
Performance
Portfolio
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Data as at: 03/02/2025
In
Objective
To achieve long-term capital growth by investing in biotechnology and other life sciences companies.
AIC sector
Management group
Company website
Launch date
06/05/1994
August
Domicile
United Kingdom
Fund manager
Ailsa Craig, Marek Poszepczynski
Dividend frequency
Semi-Annually
Wind-up provisions
The Association Articles of the company provide for Directors to put forward a proposal for the continuation of the company at the AGM at two-yearly intervals. The upcoming continuation vote is scheduled for the December 2025 AGM.
| Market Cap (m) | Total assets (m) | Price (last close) | NAV | Discount / premium (%) | Gearing (%) | Dividend yield (%) | Dividend dates | Ongoing charge (%) |
|---|---|---|---|---|---|---|---|---|
| 255.33 | 323.01 | 714.00 | 790.65 | -9.70 | 15 | 3.98 | Jul, Dec | 1.2 (31/08/2024) |
Scroll
Dividends
Dividends declared in last 12 months
| Ex-dividend date | Payment date | Dividend amount | Special dividend | Financial year |
|---|---|---|---|---|
| 19/12/2024 | 24/01/2025 | 15.560 | No | 2025 |
| 25/07/2024 | 23/08/2024 | 14.500 | No | 2024 |
Scroll
Performance (%)
| Return type | 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|---|
| International Biotechnology | Share price total return | 15.0 | 31.0 | 53.2 | 102.7 |
| Biotechnology & Healthcare AIC sector | Share price total return | 1.1 | -3.8 | -3.7 | 63.1 |
Scroll
Share structure
Number of shares
35,760,568
5,623,249
Traded volumes (number of shares)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 136,297 | 1,474,606 | 17,608,422 | 85,896,094 |
| Average | N/A | 70,921 | 69,847 | 67,918 |
Scroll
Traded values (m)
| Yesterday | 1 month | 1 year | 5 years | |
|---|---|---|---|---|
| Total | 0.97 | 10.32 | 118.80 | 596.41 |
| Average | N/A | 0.50 | 0.47 | 0.47 |
Scroll
Trading details
Top holdings
Data as at : 31/12/2024
| Investment | % of total assets |
|---|---|
| Intra-Cellular Therapies Inc | 6.0 |
| Vera Therapeutics Inc Class A | 5.9 |
| Insmed Inc | 5.3 |
| Regeneron Pharmaceuticals Inc | 4.9 |
| uniQure NV | 4.2 |
| Biomarin Pharmaceutical Inc | 3.9 |
| Incyte Corp | 3.7 |
| Ascendis Pharma AS ADR | 3.7 |
| BeiGene Ltd ADR | 3.5 |
| Scb Sholo211123b 16-Dec-2024 5.73% 16-Jan-2025 | -14.3 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
